Categories

Meta

Recent Posts

« Mournful doses of n-3 fatty acids do not cut back comprehensive regardless of main cardiovascular events
Nabi receives US service mark as a remedy for treatment and inhibition of nicotine addiction with NicVAX conjugate vaccines »

Boehringer Ingelheim announces sub-analysis arise of RE-LY whack

Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY® hearing – the largest atrial fibrillation outcomes dry run always conducted– were published in The Lancet.  The sub-analysis evaluated the rudimentary outcomes of RE-LY® in apropos to each center’s usually outmoded in corrective radius (cTTR) (INR 2.0-3.0) because patients winsome warfarin.

Survey centers were placed into ditty of four groups based on cTTR (72.6%).(1) Earliest outcomes were assessed across the three treatment arms (dabigatran etexilate 110mg DICTATE, dabigatran etexilate 150mg DICTATE, warfarin)(1) and demonstrated:

There was no impressive interaction between cTTR and iota and systemic embolism in behalf of either dabigatran etexilate 110mg DEMAND or dabigatran etexilate 150mg ENTREAT compared to warfarin (interaction>There was no notable interaction between cTTR and dominant bleeding with dabigatran etexilate 110mg ORDER (interaction>There was no meritorious interaction between cTTR and intracranial bleeding because either dabigatran etexilate 110mg TELL or dabigatran etexilate 150mg ORDER compared to warfarin (interaction>

"Well-controlled warfarin is exceedingly outstanding over the extent of the control of accomplishment in patients with atrial fibrillation; even so, we separate in clinical work there can be by variations in the flatten out of hold back," said Dr. Michael Ezekowitz, professor & villainy president, clinical scrutiny, Lankenau Inaugurate.  "The results of this sub-analysis recommend the equal of manage achieved across RE-LY essay centers did not force the effects of dabigatran etexilate compared to warfarin appropriate for throb prevention."

WELL-SPRING Boehringer Ingelheim Pharmaceuticals, Inc.

Help-Medical.net finds at this phrases:

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

This entry was posted on Sunday, August 29th, 2010 at 3:31 pm and is filed under Drug Trial. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.